Standard BioTools (Nasdaq:SLGC) - Aktienkurs, Nachrichten und Analyse

SLGC Aktienübersicht

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.

SLGC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 16.43%

Risikoanalyse

Volatiler Aktienkurs in den letzten 3 Monaten

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Standard BioTools Inc. Wettbewerber

Pacific Biosciences of California

NasdaqGS:PACB

US$400.4m

Adaptive Biotechnologies

NasdaqGS:ADPT

US$477.5m

Cryoport

NasdaqCM:CYRX

US$477.8m

Mesa Laboratories

NasdaqGS:MLAB

US$500.2m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Standard BioTools
Historische Aktienkurse
Aktueller Aktienkurs	US$2.10
52-Wochen-Hoch	US$3.79
52-Wochen-Tief	US$1.73
Beta	1.64
11 Monat Veränderung	-13.93%
3 Monate Veränderung	14.13%
1 Jahr Veränderung	-28.08%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	n/a

Aktuelle Nachrichten und Updates

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Aktionärsrenditen

	SLGC	US Life Sciences	US Markt
7D	-14.3%	0.07%	0.1%
1Y	-28.1%	1.1%	24.1%

Rendite im Vergleich zur Industrie: SLGC unter dem Niveau der Branche US Life Sciences, die im vergangenen Jahr eine Rendite von 7.8% erzielte.

Rendite vs. Markt: SLGC hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is SLGC's price volatile compared to industry and market?
SLGC volatility
SLGC Average Weekly Movement	11.4%
Life Sciences Industry Average Movement	6.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

Stabiler Aktienkurs: SLGCDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: SLGCDie wöchentliche Volatilität (11%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1999	451	Adam Taich	www.somalogic.com

Standard BioTools Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Standard BioTools im Vergleich zum Marktanteil des Unternehmens?
SLGC grundlegende Statistiken
Marktanteil	US$396.23m
Gewinn(TTM)	-US$130.38m
Umsatz(TTM)	US$81.72m

4.8x

Kurs-Umsatz-Verhältnis

-3.0x

Kurs-Gewinn-Verhältnis

Ist SLGC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SLGC Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$81.72m
Kosten der Einnahmen	US$97.89m
Bruttogewinn	-US$16.16m
Sonstige Ausgaben	US$114.22m
Umsatz	-US$130.38m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.69
Bruttomarge	-19.78%
Nettogewinnspanne	-159.54%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich SLGC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

SLGC Aktienübersicht

Belohnungen

Risikoanalyse

Standard BioTools Inc. Wettbewerber

NasdaqGS:PACB

US$400.4m

NasdaqGS:ADPT

US$477.5m

NasdaqCM:CYRX

US$477.8m

NasdaqGS:MLAB

US$500.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Consensus forecasts updated

SomaLogic Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Erträge & Einnahmen